: Peripheral artery disease (PAD), being a manifestation of systemic atherosclerosis, carries a high risk of adverse cardiovascular events. Secondary prevention medical therapies of the same magnitude as those for coronary heart disease (CAD) are also recommended for patients with PAD. Available evidence indicates that this condition remains generally underdiagnosed and undertreated. There are no reports on the management of these patients in India. Objective: To characterize the atherosclerotic risk factor profile and medication prescription pattern for patients with PAD in a tertiary care university hospital and compare this management with standard guidelines. Material and methods: Data were collected from the prescriptions of patients attending the CTVS OPD with a diagnosis of atherosclerotic PAD from July 2012 to June 2013. Results: One hundred and twenty prescriptions were analyzed. The mean (± SD) age of patients was 53 ± 7.18 years and 23.3% were women. A history of smoking, past or present, was present in 91.6% of patients. A history of ischemic heart disease was present in 25% of patients while 26.7% of patients were diabetic. The average number of cardiovascular risk factors was 2.6. The percentage of eligible patients who received a particular medication was 100% for aspirin and statins, 48.3% for ACE inhibitors, 46.7% for beta-blockers, and 66.7% for cilostazol. Conclusion: Vascular surgeons at this center use antiplatelet agents and statins. adequately for PAD. Prescription of ACE inhibitors, beta-blockers and cilostazol is low. Exercise therapy and smoking cessation need more attention.IntroductionPeripheral artery disease (PAD) is a common disorder affecting large populations of adults worldwide. Most often ... middle of paper ...... entoxyphylline) has been recorded. Prescription of medications for other purposes (e.g. antacids, analgesics or antipyretics, multivitamins) was not recorded. Medication Eligibility Assessment: Each prescription was analyzed to determine eligibility for medications intended to modify atherosclerotic risk factors (aspirin, ACE inhibitors, beta blockers, and lipids). lowering medications) and for medications for intermittent claudication (cilostazol and pentoxyphylline). Eligibility was decided based on the ACC/AHA and TASC-II guidelines for the management of patients with PAD.[11,12] All patients were considered eligible for aspirin, inhibitors of ACE, lipid-lowering drugs and cilostazol. Additionally, patients with a history of ischemic heart disease (IHD) were considered eligible for beta-blockers. Patients were considered eligible for pentoxiphylline only if cilostazol was contraindicated/not tolerated..